Torsades De Pointes Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 13, 2026 · Data accessed through Patsnap Life Sciences MCP servers.

This Torsades De Pointes Indication Strategy Report ranks the opportunity using disease burden, biological rationale, unmet need, competitive intensity and transaction signals. It is designed for biopharma portfolio, search-and-evaluation, licensing and translational teams. The analysis focuses exclusively on Torsades De Pointes; adjacent diseases are mentioned only when needed to interpret evidence or trial design.

Executive assessment

Torsades De Pointes receives an overall strategic score of 71/100. The opportunity combines an unmet-need score of 85/100, competition score of 54/100 and market-attractiveness score of 72/100. Scores are directional decision aids, not forecasts: they synthesize the MCP evidence returned on the access date and explicitly penalize crowded development landscapes.

Disease background and strategic definition

A malignant form of polymorphic ventricular tachycardia that is characterized by HEART RATE between 200 and 250 beats per minute, and QRS complexes with changing amplitude and twisting of the points. The term also describes the syndrome of tachycardia with prolonged ventricular repolarization, long QT intervals exceeding 500 milliseconds or BRADYCARDIA. Torsades de pointes may be self-limited or may progress to VENTRICULAR FIBRILLATION.

For indication strategy, the disease label is only the starting point. A credible target product profile should specify the treatable population, diagnostic pathway, severity threshold, prior-therapy requirements, measurable clinical outcomes and treatment setting. In Torsades De Pointes, value creation will depend on selecting a phenotype that is biologically coherent and commercially reachable, while avoiding a trial population so narrow that recruitment and launch become impractical.

The disease record is identified by Patsnap disease ID e8ca21317fdc47b9b3bc6b84e3e2f3a3 and MeSH identifier D016171. These identifiers help keep searches reproducible when synonyms or spelling variants change.

Epidemiology and disease-burden evidence

Evidence signal 1: Heart Disease and Stroke Statistics—2022 Update Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association

• During a mean follow-up period of 85 months, sus­ tained VT was observed in 13 of 250 (5.2%) and monomorphic VT in 9 of 250 (3.6%) patients with congenital LV aneurysms or diverticula.162 Polymorphic VT/VF Prevalence and Incidence • In the setting of AMI, the prevalence of polymorphic VT was 4.4%.163 Complications • In the setting of AMI, polymorphic VT is associated with increased mortality (17.8%).163 Torsade de Pointes Prevalence and Incidence • Among 14 756 patients exposed to QT-prolonging drugs in 36 studies, 6.3% developed QT prolonga­ tion, and 0.33% developed TdP.164 Risk Factors • An up-to-date list of drugs with the potential to cause TdP is available at a website maintained by the University of Arizona Center for Education and Research on Therapeutics.165 Awareness and Treatment (See Table 19-1) • Median annual CPR training rate for US counties was 2.39% (25th–75th percentiles, 0.88%–5.31%) according to training data from the AHA, the American Red Cross, and the Health & Safety Institute, the largest providers of CPR training in the United States.166 Training rates were lower in rural areas, counties with high proportions of Black or Hispanic residents, and counties with lower median household income. • Prevalence of reported current training in CPR was 18% and prevalence of having CPR training at some point was 65% in a survey of 9022 people in the United States in 2015.167 The prevalence of CPR training was lower in Hispanic/Latino people, older people, people with less formal education, and lower-income groups. • Those with prior CPR training include 90% of

Review the underlying epidemiology source

Evidence signal 2: Heart Disease and Stroke Statistics—2021 Update

• In a study of 1139 older adults in the CHS without HF or systolic dysfunction studied by Holter monitor (median duration, 22.2 hours), 0.011% of all heart- beats were PVCs, and 5.5% of participants had nonsustained VT. Over follow-up, the highest quar- tile of ambulatory electrocardiographic PVC burden was associated with an adjusted odds of decreased LVEF (OR, 1.13 [95% CI, 1.05–1.21]) and incident HF (HR, 1.06 [95% CI, 1.02–1.09]) and death (HR, 1.04 [95% CI, 1.02–1.06]).116 Although PVC abla- tion has been shown to improve cardiomyopathy, the association with death may be complex, rep- resenting both a potential cause and a noncausal marker for coronary or structural HD. • Among 698 patients with cardiac resynchroniza- tion therapy, 3-year risk of VT/VF was higher in patients with >10 PVCs per hour (24%) than in patients with <10 PVCs per hour (8%; aHR, 2.79 [95% CI, 1.69–4.58]).117 Monomorphic VT Prevalence and Incidence • Monomorphic VT occurred in 9 of 342 (2.6%) patients at a median of 1 (IQR, 0.25–4.75) day after PCI for chronic total occlusion of a coronary artery.118 • During a mean follow-up period of 85 months, sustained VT was observed in 13 of 250 (5.2%) and monomorphic VT in 9 of 250 (3.6%) patients with congenital LV aneurysms or diverticula.119 Polymorphic VT Prevalence and Incidence • In the setting of AMI, the prevalence of polymor- phic VT was 4.4%.120 Complications • In the setting of AMI, polymorphic VT is associated with increased mortality (17.8%).120 Torsade de Pointes Prevalence and Incidence • Among 14 756 patients exposed to QT-prolonging drugs

Review the underlying epidemiology source

Evidence signal 3: Heart Disease and Stroke Statistics—2020 Update Heart Disease and Stroke Statistics— 2020 Update

• In a study of 1139 older adults in the CHS without HF or systolic dysfunction studied by Holter moni- tor (median duration, 22.2 hours), 0.011% of all heartbeats were PVCs, and 5.5% of participants had nonsustained VT. Over follow-up, the high- est quartile of ambulatory ECG PVC burden was associated with an adjusted odds of decreased LVEF (OR, 1.13 [95% CI, 1.05–1.21]) and incident HF (HR, 1.06 [95% CI, 1.02–1.09]) and death (HR, 1.04 [95% CI, 1.02–1.06]).113 Although PVC abla- tion has been shown to improve cardiomyopathy, the association with death may be complex, rep- resenting both a potential cause and a noncausal marker for coronary or structural HD. • Among 698 patients with cardiac resynchroniza- tion therapy, 3-year risk of VT/VF was higher in patients with >10 PVCs/h (24%) than in patients with <10 PVCs /h (8%; adjusted HR, 2.79 [95% CI, 1.69–4.58]).114 Monomorphic VT Prevalence and Incidence • Among 2099 subjects (mean age 52 years; 52.2% male) without known CVD, exercise-induced non- sustained VT occurred in 3.7% and was not inde- pendently associated with total mortality.115 Polymorphic VT Prevalence and Incidence • In the setting of AMI, the prevalence of PVT was 4.4%.116 Complications • In the setting of AMI, PVT is associated with increased mortality (17.8%).116 Risk Factors • PVT in the setting of a normal QT interval is most frequently seen in the context of acute ischemia or MI.117 Torsade de Pointes Prevalence and Incidence • Among 14 756 patients exposed to QT-prolonging drugs in 36 studies, 6.3% developed QT prolonga- tion, and 0.33% developed TdP.1

Review the underlying epidemiology source

Epidemiology must be translated into an addressable population rather than copied into a revenue model. The recommended funnel is total prevalent or incident population → diagnosed population → clinically eligible segment → treated population → realistically accessible population. Analysts should separate point prevalence from lifetime prevalence, distinguish incidence from diagnosis rates, and avoid combining incompatible geographies or age bands.

For Torsades De Pointes, the highest-value next epidemiology work is to quantify diagnostic delay, severity distribution, current treatment penetration and the proportion managed in specialist centers. Those variables often move the commercial case more than a single headline prevalence statistic.

Unmet need and patient-value thesis

Unmet need in Torsades De Pointes should be framed as a measurable gap: inadequate disease control, treatment-limiting toxicity, burdensome administration, irreversible progression, delayed diagnosis, weak durability or lack of options for a defined subgroup. A program is strategically attractive when its mechanism can plausibly change one of those outcomes and when the clinical endpoint is accepted by regulators, physicians and payers.

The strongest development thesis would connect mechanism to a pre-specified responder population, demonstrate a clinically interpretable benefit, and reduce a meaningful part of the care burden. A weak thesis would rely only on statistical significance, use an endpoint disconnected from daily function, or assume that rarity automatically supports premium pricing.

Target mechanism: hERG

Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel (PubMed:10219239, PubMed:10753933, PubMed:10790218, PubMed:10837251, PubMed:11997281, PubMed:12063277, PubMed:18559421, PubMed:22314138, PubMed:22359612, PubMed:26363003, PubMed:27916661, PubMed:9230439, PubMed:9351446, PubMed:9765245). Channel properties are modulated by cAMP and subunit assembly (PubMed:10837251). Characterized by unusual gating kinetics by producing relatively small outward currents during membrane depolarization and large inward currents during subsequent repolarization which reflect a rapid inactivation during depolarization and quick recovery from inactivation but slow deactivation (closing) during repolarization (PubMed:10219239, PubMed:10753933, PubMed:10790218, PubMed:10837251, PubMed:11997281, PubMed:12063277, PubMed:18559421, PubMed:22314138, PubMed:22359612, PubMed:26363003, PubMed:27916661, PubMed:9230439, PubMed:9351446, PubMed:9765245). Forms a stable complex with KCNE1 or KCNE2, and that this heteromultimerization regulates inward rectifier potassium channel activity (PubMed:10219239, PubMed:9230439). Has no inward rectifier potassium channel activity by itself, but modulates channel characteristics by forming heterotetramers with other isoforms which are retained intracellularly and undergo ubiquitin-dependent degradation. Has no inward rectifier potassium channel activity by itself, but modulates channel characteristics by forming heterotetramers with other isoforms which are retained intracellularly and undergo ubiquitin-dependent degradation.

The proposed mechanism anchor for this landscape is KCNH2. Target selection does not imply that every Torsades De Pointes patient is target-dependent. The translational package should establish expression or pathway activity in the intended tissue, human genetic or biomarker support, pharmacodynamic tractability, a therapeutic window and evidence that target modulation changes disease-relevant biology.

Critical de-risking experiments include orthogonal target engagement assays, dose–response work in disease-relevant models, biomarker qualification, assessment of compensatory pathways and explicit off-target safety testing. Human evidence should be weighted above model-only evidence, and negative clinical results in related mechanisms should be treated as learning assets rather than ignored.

Clinical development and competitive landscape

The MCP search returned 15 matched registered studies overall. The most recent records sampled for this report are:

• NCT07374263 — Do QT-Prolonging Drugs Cause Major Adverse Cardiac Events in Hospitalized Adults? (QTP-MACE); status: Recruiting; phase: Not Applicable; sponsor(s): St. Joseph's Healthcare Hamilton, McMaster University, Canadian Institutes of Health Research; enrollment: 990000.
• NCT07014735 — Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DM; status: Terminated; phase: Not Applicable; sponsor(s): Richmond Pharmacology Ltd., Richmond Research Institute Pte Ltd; enrollment: 14.
• NCT05521451 — Clinical Cohort Study - TRUST (TRUST); status: Recruiting; phase: Not Applicable; sponsor(s): Universitätsklinikum Hamburg-Eppendorf; enrollment: 5000.

Raw trial count is not the same as commercial competition. Each program should be normalized by phase, modality, mechanism, sponsor strength, recruitment status, geography and the exact patient segment. Observational or investigator-led studies may reveal endpoint conventions and recruitment networks without representing product competition; discontinued assets may still expose safety or efficacy risks.

A differentiated Torsades De Pointes program should define its advantage against the standard of care and the likely future standard at launch, not merely today's comparator. Useful whitespace can come from earlier intervention, a biomarker-selected subgroup, superior durability, safer chronic use, simpler delivery or a combination strategy with a clear contribution from each component.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned for Torsades De Pointes. This is decision-relevant negative evidence: the indication may be under-transacted, may trade through broader disease labels, or may require target- and asset-level deal searches. It should not be interpreted as proof of zero partnering activity.

Transaction evidence should be interpreted alongside asset quality. Headline values may include contingent milestones, broad platform rights, multiple indications or undisclosed options. A defensible comparable set therefore requires matching disease, target, modality, development phase, territory and deal structure. Where direct comparables are sparse, triangulation across target-level and therapeutic-area transactions is preferable to forcing an unrelated deal into the valuation.

Potential partners will expect a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical development plan, intellectual-property position, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Early outreach is most productive when the program has a clear upcoming catalyst and a credible explanation of why the asset can win specifically in Torsades De Pointes.

Market attractiveness and access considerations

The market opportunity is shaped by more than patient count. Diagnosis infrastructure, concentration of prescribers, treatment duration, administration setting, payer controls, competing generics, monitoring requirements and geographic reimbursement all influence attainable value. For Torsades De Pointes, a launch model should test conservative, base and upside scenarios rather than assume uniform diagnosis and treatment.

Pricing power will depend on magnitude and durability of benefit, evidence quality, alternatives and budget impact. Developers should begin payer research before pivotal design so that endpoints, comparators and follow-up duration support both regulatory approval and reimbursement. Evidence generation should include health-resource use, quality of life and treatment burden when those are central to the value proposition.

Risks, evidence gaps and decision gates

• Disease-definition risk: validate that the proposed population is consistently diagnosed and recruitable.
• Biology risk: demonstrate that KCNH2 is causal or therapeutically relevant in the intended subgroup.
• Translation risk: link target engagement to a biomarker and a clinically meaningful endpoint.
• Competition risk: refresh the landscape before each investment gate and include mechanisms likely to launch first.
• Commercial risk: test diagnosis, access, pricing and adoption assumptions with physicians and payers.
• Data risk: treat zero-result searches as prompts for synonym and roll-up analysis, not definitive absence.

The recommended decision gates are: confirm epidemiology and segmentation; validate target biology in human evidence; establish a differentiated target product profile; obtain early clinical proof of mechanism; and only then scale investment toward registrational development or partnering. Each gate should have pre-agreed stop criteria.

Strategic recommendation

Torsades De Pointes merits continued evaluation with an evidence-led, milestone-based strategy. The current signal supports prioritizing a narrowly defined population where KCNH2 biology can be measured and where the clinical benefit would be meaningful relative to available care. The program should advance only if follow-up work confirms population size, mechanistic coherence, endpoint feasibility and a credible route to differentiation.

For business development, the near-term goal is not to maximize the number of outreach targets; it is to assemble a partner-ready thesis that explains the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scores in this report provide a common language for comparing the opportunity while preserving the underlying evidence and uncertainties.

Methodology and source note

This report was assembled on August 13, 2026 using Patsnap MCP tools in a reproducible sequence: disease profile retrieval, epidemiology semantic search, target profile retrieval, clinical-trial search and pharmaceutical-deal search. Results reflect the returned records and query scope on that date. Counts may change as databases update, and the analysis is not medical, regulatory or investment advice.

The ranking weights are 40% unmet need, 25% inverse competitive intensity and 35% market attractiveness. Qualitative judgments are informed by disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Readers should rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio decision.

Conclusion

Torsades De Pointes offers a tractable strategic question: can a biologically grounded program deliver a material patient benefit in a clearly identifiable population and do so with sufficient differentiation to earn adoption? The evidence assembled here gives teams a starting map, while the identified gaps define the next diligence plan. Use the linked MCP marketplace to refresh the evidence as programs, trials and transactions evolve.